ÿÄ꣬ȫÊÀ½çÓдóÔ¼3ÒÚÈ˻ᱻϸÁ£¼¬ÇòÌг棨hydatid tapeworms£©»òѪÎü³æ£¨schistosomes£©µÈ¼ÄÉúÐÔ±âÐζ¯Îparasitic flatworms£©¸ÐȾ¡£ÕâЩ¼ÄÉú³æ¸ÐȾÈËÌåÖ®ºó»á´øÀ´¶àÖÖ¼²²¡£¬±ÈÈç·ÎÄÒÐÍ°ü³æ²¡£¨alveolar/cystic echinococcosis£©ºÍ¸ÎÆ¢¡¢ÃÚÄòÉúֳϵͳѪÎü³æ²¡£¨hepatosplenic/urogenital schistosomiasis£©µÈ£¬ÕâЩ¼²²¡ÍùÍù¶¼ÊÇÂýÐÔ¼²²¡£¬¶øÇÒ³£³£¶¼»áÖÂÈËËÀÍö¡£ÔÚÁªºÏ¹úÊÀ½çÎÀÉú×éÖ¯£¨WHO£©¹«²¼µÄ17ÖÖ¡¶±»È˺öÊÓµÄÈÈ´ø¼²²¡£¨neglected tropical diseases£©Ãû¼¡·µ±ÖУ¬ÕâЩ¼²²¡Ò²ºÕÈ»ÔÚÁС£Ã¿ÄêÈ«ÊÀ½çÒòΪÕâЩ¼²²¡»á¼õÉÙ´óÔ¼400ÍòÉ˲е÷ÕûÉúÃüÄ꣨disability-adjusted life years£¬Ö¸´Ó·¢²¡µ½ËÀÍöËùËðʧµÄÈ«²¿½¡¿µÊÙÃüÄ꣬°üÀ¨ÒòÔçËÀËùÖµÄÊÙÃüËðʧÄêºÍÉ˲ÐËùÖµĽ¡¿µÊÙÃüËðʧÄêÁ½²¿·Ö£©£¬¶øÇÒÕâ¸öÊý×ÖÒªÔ¶Ô¶µÍÓÚʵ¼Ê·¢ÉúµÄÇé¿ö¡£ÎÒÃǹýÈ¥Ò»Ö±¶¼ÈÏΪÕâÀ༲²¡½ö½ö¾ÖÏÞÔÚÈÈ´øºÍÑÇÈÈ´øµØÇø£¬ÒòΪÎÒÃÇÏàÐÅÖ»ÓÐÕâЩµØÇø²Å¾ß±¸¸ÃÀ༲²¡£¨¼ÄÉú³æ£©´«²¥µÄÌõ¼þ£¬±ÈÈçÏàÓ¦µÄ´«²¥ËÞÖ÷¡£µ«ÊÇÏÖÔÚÕâЩËÞÖ÷ÒѾ´«²¥µ½ÁËÅ·ÖÞ£¬¶øÇÒÔÚÆäËû´ó½£¨ÖÞ£©Ò²¶¼¾ß±¸ÕâЩ¼²²¡´«²¥µÄÊÊÒËÌõ¼þ¡£ÓÉÓÚȱ·¦ÏàÓ¦µÄÒßÃ磬ËùÒÔÎÒÃÇÖ»ÄÜ£¨¹ý¶È£©ÒÀÀµÏà¹ØµÄ»¯ÁÆÒ©Î³ý·ÇÄܹ»ÓÐÐÂÒ©³öÏÖ¡£
ΪÁ˼ӿìÒßÃçºÍÐÂÒ©µÄÑз¢½ø³Ì£¬¼ÓÉîÎÒÃǶԼÄÉú³æµÄÈÏʶºÍÁ˽⣬·Ç³£ÓбØÒªÔÚ¼ÄÉú³æ¼°Ïà¹Ø¼²²¡µÄ¿ÆÑй¤×÷ÖÐÓõ½×îÏȽøµÄ¿ÆÑм¼ÊõºÍÊֶΡ£ÔÚ²¸È鶯ÎïÑо¿·½Ã棬ÓÉÓÚ¸Éϸ°û´ó·¶Î§Óձ䣨large scale mutagenesis£©¼¼ÊõµÄ¹ã·ºÓ¦Óã¬ÒѾȡµÃÁ˲»´íµÄ½øÕ¹¡£×î½ü£¬Ï¸°û¼¼Êõ¼°»ùÒò×é±à¼¼¼ÊõÏà½áºÏµÄвßÂÔ£¨cell-focused approaches coupled with genome editing£©ÓÖ¿ªÊ¼Á÷ÐÐÆðÀ´¡£ÕâÖÖ²ßÂÔ£¨ÖصãÊÇCRISPR-Cas9¼¼Êõ£©¸øÕæºËÉúÎïµÄÒÅ´«Í»±ä±íÐÍ·ÖÎö¹¤×÷£¨genetic-mutational-phenotypic yses£©´øÀ´Á˸ïÃüÐԵĸı䡣Ïà±È֮ϣ¬¼ÄÉú³æÏà¹ØÑо¿¹¤×÷¾ÍÏÔµ*************************÷ÏÔµÄÖͺóÁË¡£À§ÄÑÔÚÓÚ¼ÄÉú³æÒòΪÓи´ÔÓµÄÉú»îÊ·£¨ÍùÍù¶¼ÓÐÁ½¸ö±ØÐèËÞÖ÷£©£¬ËùÒÔºÜÄÑÔÚʵÑéÊÒÀï½øÐÐÅàÑøºÍ²Ù×÷¡£ÁíÍâÓÉÓÚºÜÄѶԼÄÉú³æ½øÐÐÒÅ´«Ñ§»òϸ°ûѧ²Ù×÷£¬ËùÒÔÕâЩ×îеÄÊÔÑé¼¼ÊõÒ²±È½ÏÄÑÓÚÓ¦ÓÃÓÚ¼ÄÉú³æÑо¿¹¤×÷µ±ÖС£
¾¡¹Ü´æÔÚÉÏÊöÕâЩÀ§ÄѺÍÎÊÌ⣬ÔÚѪÎü³æת»ùÒòÑо¿£¨schistosome transgenesis£©¡¢Æ÷¹Ù·ÖÀ루organ isolation£©ºÍ¸Éϸ°û¼ø¶¨£¨stem cell characterization£©£¬ÒÔ¼°Ï¸Á£¼¬ÇòÌг棨echinococcal, hydatid tapeworm£©Ô´úϸ°ûÅàÑøµÈ·½Ã滹ÊÇÈ¡µÃÁËÒ»¶¨µÄ½øÕ¹£¬ÕâҲԤʾ׿ÄÉú³æÑо¿¼´½«¿çÈëÒ»¸öոеÄʱ´ú¡£×÷ΪȫÉúÃüÌå»òϸ°ûת»ùÒò¹¤×÷µÄÇ°Ðò¹¤×÷ºÍ×¼±¸¹¤×÷£¬ÔÚ֮ǰµÄ15Äêʱ¼äÀ¿ÆÑÐÈËÔ±ÃÇÒѾ½èÖúת¼ºó»ùÒò³ÁĬ£¨posttranscriptional gene silencing£©¼¼Êõ£¬¶ÔѪÎü³æ½øÐÐÁË´óÁ¿µÄ¹¦ÄÜȱʧÑо¿£¨loss-of-function studies£©¡£µ«ÊÇÕâÖÖÊÔÑé²Ù×÷¼¼ÊõÖ»Äܹ»µÃµ½ÔÝʱÐԵıíÐ͸ı䣬¶øÇÒÍùÍù¶¼²»Äܹ»³ä·ÖÉø͸£¬ÁíÍâÒ²ÄÑÒÔÍƹ㵽ÆäËû¼ÄÉú³æÑо¿¹¤×÷µ±ÖС£ÒÔÖÊÁ£ÎªÔØÌ壬¶ÔѪÎü³æ½øÐÐת»ùÒò¹ý±í´ï²Ù×÷£¬Ê¹Æä»ñµÃijÏÄÜ»ò±íÐÍ£¨Gain of-function£©£¬ÕâÔÚÔÀíÉÏÒ²ÊÇ¿ÉÐеġ£µ«ÊÇÕâÒ²ºÍת¼ºó»ùÒò³ÁĬ¼¼Êõ´æÔÚͬÑùµÄÎÊÌâ¡£
¿ª·¢Ò»Ì×Îȶ¨µÄ»ùÒò²Ù¿ØÊÔÑé¼¼Êõ¾Í³ÉΪÁ˵±ÎñÖ®¼±¡£*********µÄÊÇ£¬¿Æѧ¼ÒÃÇ×î½ü·¢ÏÖÁËÊó°×Ѫ²¡²¡¶¾£¨murine leukemia viruses£©ÕâÖÖ¼ÙÄæת¼²¡¶¾£¨pseudotyped retroviruses£©£¬ÒÔ¼°piggyBacת×ù×Ó£¨transposons£©¡£ÕâЩ¹¤¾ß¶¼Äܹ»½«ÍâÔ´µÄת»ùÒòתÈëѪÎü³æµÄ8ÌõȾɫÌ壨°üÀ¨Éúֳϸ°ûȾɫÌ壩µ±ÖС£½«ÕâÖÖ¼¼ÊõÓ¦ÓÃÓÚÆäËû¼ÄÉú³æ£¬ÒÔ¼°ÓÐÑ¡ÔñÐÔת»ùÒò»ùÒò×éÕûºÏ£¨transgene genome integration£©¹¤×÷£¬Õⶼ½«´Ù½ø¼ÄÉú³æµ¥¸ö»ùÒò¹¦ÄÜÑо¿¹¤×÷µÄ¿ªÕ¹¡£
³ýÁËÉÏÊöÕâЩת»ùÒòÊÔÑé¼¼Êõ·½ÃæµÄ½øÕ¹Ö®Í⣬ÔÚ¼ÄÉú³æϸ°ûÅàÑø·½ÃæҲȡµÃÁËÒ»¶¨µÄ³É¹ûºÍ½øÕ¹¡£¹¤×÷µÄÖصãÖ÷Òª¼¯ÖÐÔÚ¸Éϸ°û£¨stem cells£©£¬Ò²±»³Æ×÷Éú·¢Ï¸°û£¨germinative cells£©»ò³ÉÌåδ·Ö»¯Ï¸°û£¨neoblasts£©ºÍ¼ÄÉú³æ¶¨¾ÓµÄËÞÖ÷×é֯ϸ°û£¨ÒòΪÕâЩËÞÖ÷ϸ°ûÄܹ»×ÔÎÒ¡¢·Ö»¯£¬Í¬Ê±Ò²°ïÖú¼ÄÉú³æ·¢ÓýºÍ½ø»¯£©ÕâÁ½¸ö·½Ãæ¡£¶ÔÓÚѪÎü³æ¶øÑÔ£¬Ä¿Ç°ÒѾ±È½ÏÈÝÒ×·ÖÀ븻º¬¸Éϸ°ûµÄ¼ÄÉú³æÐÔÏÙÆ÷¹Ù£¨gonad£©£¬Ò²¿ÉÒÔ¼ø¶¨ÔöÖ³ÖеijÉÌå¸Éϸ°û£¨somatic proliferating stem cells£©£¬ÒÔ¼°¶ÔѪÎü³æϸ°û½øÐÐÓÐÏÞ´úÊý£¨limited-passage£©µÄÌåÍâÅàÑø¡£Ï¸Á£¼¬ÇòÌг棨echinococcal tapeworms£©µÄϸ°ûÅàÑøϵͳҲȡµÃÁ˲»´íµÄ½øÕ¹£»Ò²¿ÉÒÔÌáÈ¡¶à·¿¼¬ÇòÌг棨Echinococcus multilocularis£©µÄ¸Éϸ°û£¬²¢ÇÒ½øÐÐÁ¬ÐøÅàÑø¼°·Ö»¯£»»¹´ÓϸÁ£¼¬ÇòÌг棨E. granulosus£©ÖзÖÀëµÃµ½ÁËÓÀÉú»¯µÄϸ°ûϵ¡£ËäȻĿǰÈÔÔÚÑо¿Ö®ÖУ¬µ«ÒѾȷ¶¨£¬ÕâЩ¾ß±¸ÔöÖ³ÄÜÁ¦ºÍ·Ö»¯ÄÜÁ¦µÄ¼ÄÉú³æÓÀÉú»¯Ï¸°ûϵ½«ÓÐÍû°ïÖú¿ÆÑÐÈËÔ±ÃÇÈÆ¿ªÔÚ¼ÄÉú³æÑо¿¹¤×÷ÖÐ×îÈÃÈËÍ·Í´µÄÉú»îÊ·ÎÊÌâ¡£
ÔËÓûùÒò×é±à¼¼¼Êõ£¨genome editing£©ºÍÓëѪÎü³æ¼°Ï¸Á£¼¬ÇòÌгæϸ°ûÅàÑøºÍϸ°ûÉúÎïѧÏà¹ØµÄ֪ʶ£¬¿ª·¢³öÎȶ¨µÄת»ùÒò¼ÄÉú³æƷϵ£¬ÒÔ¼°¶ÔÕâЩ¼ÄÉú³æÀ´Ô´µÄϸ°û½øÐи÷ÖÖÊÔÑéºÍÑо¿ÒѾ²»ÔÙÊÇÒ£²»¿É¼°µÄÃÎÏëÁË¡£½èÖúÄæת¼²¡¶¾ÔØÌ壬Íùϸ°ûÄÚתÈëCRISPR-Cas9-RNA£¬ÕâÒѾ³ÉΪÁËÖƱ¸Îȶ¨×ª»ùÒò¼ÄÉú³æ×î·½±ã¡¢×îÓÐЧµÄ¼¼Êõ¡£ÓÐÁËÕâÌ×¼¼Êõ£¬¶Ô¼ÄÉú³æ½øÐлùÒòÇóý»ò±à*****ÇøÆÆ»µµÈÊÔÑ飬ÒÔ´ËÀ´Ñо¿¸Ã»ùÒòµÄ¹¦ÄÜ£¬Õâ¾Í²»ÔÙÊÇÄÑÌâÁË¡£¶ÔÓÚ´ÓʼÄÉú³æÑо¿¹¤×÷µÄ¿ÆÑÐÈËÔ±¶øÑÔ£¬¿ª·¢×ª»ùÒò¼ÄÉú³æºÍ¿ª·¢Îȶ¨µÄת»ùÒòϸ°ûϵҲ½«²»ÔÙÊÇÄÑÊ£¬ÒòΪËûÃÇÒѾӵÓÐÁ˺ʹÓÊÂÆäËûÉúÎïѧÑо¿µÄ¿ÆÑÐÈËԱͬÑùµÄÎäÆ÷¡£
´ÓʼÄÉú³æÑо¿¹¤×÷µÄ¿ÆÑÐÈËÔ±ÃÇÒ²ÊǵÚÒ»´ÎÓµÓÐÁËÕâÑùµÄ×ÊÔ´£¬Äܹ»ÓÃÀ´½â¾öÒ»Ö±·Á°ÐÂÒ©Ñз¢¹¤×÷£¬ÓйؼÄÉú³æ×î»ù±¾µÄ½ø»¯¡¢ÉúÎïҽѧºÍÃâÒßѧÏà¹ØµÄÎÊÌ⣬½ø¶ø´Ù½øÏà¹ØÐÂÒ©µÄÑз¢¹¤×÷¡£±ÈÈç¼ÄÉú³æÊÇÈçºÎÔË×÷ÓÀÉú»¯»úÖƵģ¿¼´¼ÄÉú³æ¸Éϸ°ûÈçºÎÔÚ¸´ÔÓµÄÉú»îÊ·¹ý³ÌÖУ¬¸³Óè¼ÄÉú³æ·¢Óý¿ÉËÜÐÔ£¨developmental plasticity£©£¬°üÀ¨ÎÞÐÔ·±Ö³¼°ÓÐÐÔ·±Ö³½×¶Î£¿±ÈÈçÒÔ¼¬ÇòÌг棨Echinococcus£©ÎªÀý£¬¸ß¶ÈÔöÖ³µÄÎÞÐÔÉúÖ³¹ý³Ì»á²úÉú´óÁ¿µÄÓ׳棨larvae£©£¬Õâ¶ÔÓÚÈ˹¤¸ÉÔ¤»á²»»áÊÇÒ»¸ö»ú»áÄØ£¿¼ÄÉú³æÓëËÞÖ÷Ö®¼ä³¤Æڵļģ¨¹²£©Éú¹ØϵÊÇÈçºÎÐγɵģ¬Ë«·½ÓÖÊÇÈçºÎ´ÓÖлñÒ沢ά³ÖÕâÖÖ¹ØϵµÄ£¿ËÞÖ÷Ò»µ©±»¼ÄÉú³æ¸ÐȾ£¬ÌåÄھͻá³öÏÖ¼ÄÉú³æ½éµ¼µÄÃâÒßµ÷¿Ø·´Ó¦£¨helminth-mediated
host immunomodulation£©ºÍËÞÖ÷½éµ¼µÄ¼ÄÉú³æÇå³ý·´Ó¦£¨host-mediated parasite elimination£©£¬ÕâÁ½ÖÖÃâÒß·´Ó¦Ö®¼ä»¥ÏྺÕù£¬¶¼Ï£ÍûÄܹ»Ê¤³öÒ»³ï¡£ÔÙ±ÈÈ磬ÄêÁäÏà¹ØÃâÒßÁ¦£¨age-dependent immunity£©¿É¼ûÓÚ¸ÐȾÁËѪÎü³æµÄÈËÀà¸ÐȾÕߣ¬µ«ÊÇÔÚÒßÇø£¬¶ùͯ²ÅÊÇ×îÖ÷ÒªµÄ±»¸ÐȾÕß¡£ÕâЩÏÖÏ󱳺óµÄ·Ö×Ó»úÖÆÊÇʲô£¿ÕâЩÏÖÏóÓÖÄܹ»ÎªÎÒÃÇ¿ª·¢¿¹¼ÄÉú³æÐÂÒ©ÌṩÄÄЩ»ú»áºÍ;¾****************Ø£¿
²ÉÓÃ×îÏȽøµÄÉúÎï¿Æѧ¼¼ÊõÀ´¶Ô¸¶ÕâЩ±»ºöÊӵIJ¡ÔÌåºÍ¼²²¡£¬ÓпÉÄÜ»á´øÀ´Ò»ÏµÁд´Ð£¬°ïÖúÎÒÃǸü¼ÓÉîÈëµØÈÏʶºÍÁ˽âÕâЩº¦È˳æµÄÉúÎïѧ±¾ÖÊ¡£ÕâЩÐÅÏ¢¿ÉÒÔ°ïÖúÎÒÃǸ㶨ÕâЩº¦È˳档
ÔÎļìË÷£º
Karl F. Hoffmann, Paul J. Brindley, Matthew Berriman. (2014) Halting harmful helminths. Science, 346:168-169.
Eason/±àÒë
ת×ÔÉúÃü°ÂÃØ